EP2347009A4 - Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type - Google Patents

Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Info

Publication number
EP2347009A4
EP2347009A4 EP09821173A EP09821173A EP2347009A4 EP 2347009 A4 EP2347009 A4 EP 2347009A4 EP 09821173 A EP09821173 A EP 09821173A EP 09821173 A EP09821173 A EP 09821173A EP 2347009 A4 EP2347009 A4 EP 2347009A4
Authority
EP
European Patent Office
Prior art keywords
gene
expressed protein
tumor type
protein targets
signature sets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09821173A
Other languages
German (de)
French (fr)
Other versions
EP2347009A2 (en
Inventor
Hoff Daniel D Von
Robert J Penny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caris Life Sciences Inc
Original Assignee
Caris MPI Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caris MPI Inc filed Critical Caris MPI Inc
Priority to EP16158951.0A priority Critical patent/EP3075864A1/en
Publication of EP2347009A2 publication Critical patent/EP2347009A2/en
Publication of EP2347009A4 publication Critical patent/EP2347009A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30—Data warehousing; Computing architectures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Theoretical Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioethics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
EP09821173A 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type Withdrawn EP2347009A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP16158951.0A EP3075864A1 (en) 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10533508P 2008-10-14 2008-10-14
US10692108P 2008-10-20 2008-10-20
PCT/US2009/060630 WO2010045318A2 (en) 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP16158951.0A Division EP3075864A1 (en) 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Publications (2)

Publication Number Publication Date
EP2347009A2 EP2347009A2 (en) 2011-07-27
EP2347009A4 true EP2347009A4 (en) 2012-05-30

Family

ID=42107198

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09821173A Withdrawn EP2347009A4 (en) 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EP16158951.0A Withdrawn EP3075864A1 (en) 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP16158951.0A Withdrawn EP3075864A1 (en) 2008-10-14 2009-10-14 Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type

Country Status (6)

Country Link
US (5) US20100113299A1 (en)
EP (2) EP2347009A4 (en)
CN (2) CN106153918A (en)
CA (1) CA2739675C (en)
IL (1) IL212349A0 (en)
WO (1) WO2010045318A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1848414T3 (en) 2005-02-03 2011-10-31 Wyeth Llc Method for treating gefitinib resistant cancer
PE20070763A1 (en) 2005-11-04 2007-08-08 Wyeth Corp ANTINEOPLASTIC COMBINATIONS OF AN INHIBITOR OF mTOR, TRASTUZUMAB AND / OR HKI-272
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
RU2008146868A (en) * 2006-05-18 2010-06-27 Кэрис МПИ, Инк.445 Норт Фифс Стрит, 3-ий Флор, Феникс, Аризона 85004, США (US) SYSTEM AND METHOD FOR DETERMINING PERSONALIZED MEDICAL INTERVENTION IN A DISEASE
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
CN102641270A (en) 2008-06-17 2012-08-22 惠氏有限责任公司 Antineoplastic combinations containing HKI-272 and vinorelbine
CN102202667A (en) 2008-08-04 2011-09-28 惠氏有限责任公司 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
MX356593B (en) 2009-04-06 2018-06-05 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer.
EP2427575B1 (en) 2009-05-07 2018-01-24 Veracyte, Inc. Methods for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
EP2524231B1 (en) 2010-01-13 2017-06-28 Wyeth LLC A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR
EP3572528A1 (en) 2010-09-24 2019-11-27 The Board of Trustees of the Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
CN102094084B (en) * 2010-11-24 2012-09-19 中山大学附属第三医院 Fluorescent quantitative PCR (Polymerase Chain Reaction) method and kit for detecting EphA2 gene expression level and application thereof
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US20130254547A1 (en) * 2012-03-23 2013-09-26 International Business Machines Corporation Encrypted transmission to and storage of surprisal data
US10353869B2 (en) 2012-05-18 2019-07-16 International Business Machines Corporation Minimization of surprisal data through application of hierarchy filter pattern
CA2881627A1 (en) 2012-08-16 2014-02-20 Genomedx Biosciences Inc. Cancer diagnostics using biomarkers
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3314027A4 (en) 2015-06-29 2019-07-03 Caris Science, Inc. Therapeutic oligonucleotides
US10941176B2 (en) 2015-07-28 2021-03-09 Caris Science, Inc. Therapeutic oligonucleotides
US10731166B2 (en) 2016-03-18 2020-08-04 Caris Science, Inc. Oligonucleotide probes and uses thereof
US11293017B2 (en) 2016-05-25 2022-04-05 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
EP3888021B1 (en) 2018-11-30 2024-02-21 Caris MPI, Inc. Next-generation molecular profiling
EP4069865A4 (en) 2019-12-02 2023-12-20 Caris MPI, Inc. Pan-cancer platinum response predictor

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013431A (en) * 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
US5610281A (en) * 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5710001A (en) * 1994-08-12 1998-01-20 Myriad Genetics, Inc. 17q-linked breast and ovarian cancer susceptibility gene
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5837492A (en) * 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
IL124620A0 (en) * 1995-12-18 1998-12-06 Myriad Genetics Inc Chromosome 13-linked breast cancer susceptibility gene
US5895748A (en) * 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
US6150514A (en) * 1997-04-09 2000-11-21 University Of Utah Research Foundation 14 Kilobase deletion in the promoter region of BRCA1 in a breast cancer family
EP1131470A4 (en) * 1998-10-28 2004-11-10 Vysis Inc Cellular arrays and methods of detecting and using genetic disorder markers
DK1151300T3 (en) * 1998-12-23 2010-07-12 Medsaic Pty Ltd Assay for detection of a binding partner
US6613510B2 (en) * 1999-04-28 2003-09-02 Mayo Foundation For Medical Education And Research Methods and probe sets for determining prostate cancer prognosis
WO2001075172A1 (en) * 2000-03-31 2001-10-11 University Of Southern California Epigenetic sequences for esophageal adenocarcinoma
US6812023B1 (en) * 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
DE10043591A1 (en) * 2000-09-01 2002-03-14 Max Delbrueck Centrum Procedure for the detection of resistance profiles of tissues and cell lines
US8613907B2 (en) * 2000-10-12 2013-12-24 University Of Rochester Compositions that inhibit proliferation of cancer cells
CA2429824A1 (en) * 2000-11-28 2002-06-06 Surromed, Inc. Methods for efficiently mining broad data sets for biological markers
US20040265813A1 (en) * 2001-07-05 2004-12-30 Teiji Takechi Dna arrays for measuring sensitivity to anticancer agent
US7529685B2 (en) * 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
BRPI0214840B8 (en) * 2001-12-21 2021-05-25 The Wellcome Trust methods for detecting human oncogenic mutations, automated methods for detecting a mutation, and method and assay for identifying one or more compounds having anti-proliferative activity
JP3481231B2 (en) * 2002-03-05 2003-12-22 三洋電機株式会社 Organic electroluminescent display device and method of manufacturing the same
JP2005519624A (en) * 2002-03-13 2005-07-07 ジェノミック ヘルス， インコーポレイテッド Gene expression profiling in biopsy tumor tissue
WO2003104474A2 (en) * 2002-06-07 2003-12-18 Myriad Genetics, Inc Large deletions in human brca1 gene and use thereof
DK1388734T3 (en) * 2002-08-01 2004-05-03 Mtm Lab Ag Method for solution-based diagnosis
AT500648B1 (en) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie SET FOR THE TREATMENT OF CANCER PATIENTS
JP4939055B2 (en) * 2002-11-13 2012-05-23 トマス ジェファソン ユニバーシティ Compositions and methods for diagnosis and treatment of cancer
EP1597391B1 (en) * 2003-02-20 2008-10-29 Genomic Health, Inc. Use of intronic rna to measure gene expression
WO2004089073A2 (en) * 2003-04-03 2004-10-21 Genpath Pharmaceuticals, Incorporated Inducible breast cancer model
US20040202658A1 (en) * 2003-04-09 2004-10-14 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor
US7361460B2 (en) * 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases
US20050084913A1 (en) * 2003-04-22 2005-04-21 Maxygen, Inc. Novel tumor-associated antigens
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7319007B2 (en) * 2003-06-12 2008-01-15 Pomeranian Academy Of Medicine Determining a predisposition to cancer
US20050026194A1 (en) * 2003-06-20 2005-02-03 Tularik Inc. Gene amplification and overexpression in cancer
US7526387B2 (en) * 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
EP1668152B1 (en) * 2003-08-28 2008-08-06 Ipsogen Identification of an erbb2 gene expression signature in breast cancer
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
KR101289774B1 (en) * 2004-03-31 2013-08-07 다나-파버 캔서 인스티튜트 인크. Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
US7871769B2 (en) * 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
CA2566519C (en) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
US20080090233A1 (en) * 2004-05-27 2008-04-17 The Regents Of The University Of Colorado Methods for Prediction of Clinical Outcome to Epidermal Growth Factor Receptor Inhibitors by Cancer Patients
WO2006039563A2 (en) * 2004-09-30 2006-04-13 Epigenomics Ag Method for providing dna fragments derived from an archived sample
WO2006050475A2 (en) * 2004-11-03 2006-05-11 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with neurological diseases
US7442507B2 (en) * 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
US8349555B2 (en) * 2005-03-16 2013-01-08 Gennadi V. Glinsky Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
EP1872124A4 (en) * 2005-04-19 2008-06-11 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20090061422A1 (en) * 2005-04-19 2009-03-05 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP1722231A3 (en) * 2005-04-27 2009-03-11 MPB MelTec Patent- und Beteiligungsgesellschaft mbH Method for identification of somatic stem cells
US20090118175A1 (en) * 2005-05-06 2009-05-07 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer
US20070020657A1 (en) * 2005-05-20 2007-01-25 Grebe Stefan K Methods for detecting circulating tumor cells
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007072220A2 (en) * 2005-09-12 2007-06-28 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing cancer
US20070172844A1 (en) * 2005-09-28 2007-07-26 University Of South Florida Individualized cancer treatments
EP1945802A1 (en) * 2005-10-12 2008-07-23 Erasmus University Medical Center Rotterdam Method to diagnose or screen for inflammatory diseases
AU2006308847C1 (en) * 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US20090215642A1 (en) * 2005-12-09 2009-08-27 Knudson Alfred G Methods and Compositions for Assessing Alterations in Gene Expression Patterns in Clinically Normal Tissues Obtained from Heterozygous Carriers of Mutant Genes Associated with Cancer and Methods of Use Thereof
JP2007175021A (en) * 2005-12-28 2007-07-12 Sysmex Corp Lymph node metastasis marker of colon cancer
US7593913B2 (en) * 2006-01-11 2009-09-22 Siemens Medical Solutions Usa, Inc. Systems and method for integrative medical decision support
CA2645310A1 (en) * 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US20090098538A1 (en) * 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy
CA2648021A1 (en) * 2006-03-31 2007-10-11 Ordway Research Institute, Inc. Prognostic and diagnostic method for cancer therapy
WO2007128884A1 (en) * 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
RU2008146868A (en) * 2006-05-18 2010-06-27 Кэрис МПИ, Инк.445 Норт Фифс Стрит, 3-ий Флор, Феникс, Аризона 85004, США (US) SYSTEM AND METHOD FOR DETERMINING PERSONALIZED MEDICAL INTERVENTION IN A DISEASE
JP2009539836A (en) * 2006-06-05 2009-11-19 ジェネンテック・インコーポレーテッド Prolonged survival of cancer patients with elevated levels of EGF or TGF-α
US8288369B2 (en) * 2006-06-27 2012-10-16 University Of South Florida Delta-tocotrienol treatment and prevention of pancreatic cancer
US20080014598A1 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Phospho-specific antibodies to pi3k regulatory subunit and uses thereof
US7999080B2 (en) * 2006-07-13 2011-08-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
CN101501695A (en) * 2006-08-11 2009-08-05 皇家飞利浦电子股份有限公司 Systems and methods for associating nucleic acid profiles and proteomic profiles with healthcare protocols and guidelines in a decision support system
EP1892303A1 (en) * 2006-08-22 2008-02-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods for identifying therapeutical targets in tumors and for determining and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung
US20090280493A1 (en) * 2006-09-08 2009-11-12 Siemens Healthcare Diagnostics Inc. Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia
WO2008050356A1 (en) * 2006-10-27 2008-05-02 Decode Genetics Cancer susceptibility variants on chr8q24.21
AU2007334343A1 (en) * 2006-12-15 2008-06-26 Ordway Research Institute, Inc. Treatments of therapy-resistant diseases comprising drug combinations
US9353415B2 (en) * 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
US20080226645A1 (en) * 2007-01-10 2008-09-18 Wyeth Methods and compositions for assessment and treatment of asthma
JP2010516786A (en) * 2007-01-26 2010-05-20 ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション，インコーポレーテッド Modification of exosome components for use as a vaccine
US20100055724A1 (en) * 2007-01-26 2010-03-04 University Of Louisville Research Foundation, Inc. Methods of detecting autoantibodies for diagnosing and characterizing disorders
JP2010528585A (en) * 2007-02-26 2010-08-26 ジョン ウェイン キャンサー インスティテュート Usefulness of B-RAF DNA mutations in the diagnosis and treatment of cancer
CA2706881A1 (en) * 2007-11-30 2009-06-11 Brian Z. Ring Tle3 as a marker for chemotherapy
DK2294215T3 (en) * 2008-05-12 2013-04-22 Genomic Health Inc Tests to predict cancer patients' response to various chemotherapeutic treatment options
US20100069298A1 (en) * 2008-09-16 2010-03-18 Robert Penny Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GYURKOCZA BOGLARKA ET AL: "Antileukemic activity of shepherdin and molecular diversity of Hsp90 inhibitors", JOURNAL OF THE NATIONAL CANCER INSTITUTE (CARY), vol. 98, no. 15, August 2006 (2006-08-01), pages 1068 - 1077, XP002672777, ISSN: 0027-8874 *
PADUANO FRANCESCO ET AL: "Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 1, January 2006 (2006-01-01), pages 179 - 186, XP002672776, ISSN: 1535-7163 *

Also Published As

Publication number Publication date
US20100113299A1 (en) 2010-05-06
IL212349A0 (en) 2011-06-30
CA2739675C (en) 2020-12-01
US20140149136A1 (en) 2014-05-29
CA2739675A1 (en) 2010-04-22
US20120015843A1 (en) 2012-01-19
US20140149137A1 (en) 2014-05-29
WO2010045318A2 (en) 2010-04-22
WO2010045318A3 (en) 2010-08-19
EP3075864A1 (en) 2016-10-05
CN106153918A (en) 2016-11-23
US20140057986A1 (en) 2014-02-27
EP2347009A2 (en) 2011-07-27
CN102232117A (en) 2011-11-02

Similar Documents

Publication Publication Date Title
IL212349A0 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
HK1204062A1 (en) Lung cancer biomarkers and uses thereof
IL233188A0 (en) Methods for assessing rna patterns
EP2591126A4 (en) Gene signatures for cancer prognosis
ZA201102287B (en) Porphobilinogen deaminase gene therapy
EP2183393A4 (en) Microrna signatures in human ovarian cancer
IL223295A0 (en) Lung cancer biomarkers and uses thereof
EP2125032A4 (en) Treating cancer with viral nucleic acid
WO2012030840A9 (en) Gene signatures for cancer diagnosis and prognosis
EP2683643A4 (en) Prostate cancer cell lines, gene signatures and uses thereof
GB0816778D0 (en) Gene silencing
EP2744919A4 (en) Gene signatures for lung cancer prognosis and therapy selection
GB0811413D0 (en) Gene expression signatures for lung cancers
EP2601314A4 (en) Prognostic gene signatures for non-small cell lung cancer
GB0904957D0 (en) Tumour gene profile
GB0714573D0 (en) Marker gene
PT2681532E (en) Dna and/or rna determination from uv-vis spectrophotometer data
GB2465088A8 (en) Methods for assessing RNA patterns
EP2185706A4 (en) Improved gene silencing methods
EP2352825A4 (en) C12orf48 as a target gene for cancer therapy and diagnosis
EP2217721A4 (en) Osteoarthritis gene therapy
EP2262541A4 (en) C2orf18 as target gene for cancer therapy and diagnosis
EP2616813A4 (en) Host supported genetic biosensors
GB0903562D0 (en) RNA molecules
GB2443265B (en) Magnetic signature assessment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110516

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G06F 19/00 20110101ALI20120412BHEP

Ipc: C12N 15/12 20060101ALI20120412BHEP

Ipc: C12Q 1/68 20060101AFI20120412BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120426

17Q First examination report despatched

Effective date: 20130919

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160308